Conversely, KMT5B dysregulation is associated with diverse pathologies: deficiency is linked to glioblastoma, sarcoma, and neurodevelopmental disorders, whereas overexpression correlates with hepatocellular carcinoma and chronic myelogenous leukemia. This evidence concerns the gene KMT5B and sarcoma.